GPC3 and hepatocellular carcinoma: GC33 (a.k.a. codrituzumab) is a humanized monoclonal IgG1 specific for GPC3, which has been evaluated in a phase II clinical trial in patients with advanced HCC who had previously progressed on sorafenib.